For the year ending 2025-12-31, KRYS made $389,130K in revenue. $206,157K in net income. Net profit margin of 52.98%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Product revenue, net | 389,130 | |||
| Cost of goods sold | 23,049 | |||
| Research and development | 58,045 | |||
| Selling, general and administrative | 146,741 | |||
| Litigation settlement | 0 | |||
| Total operating expenses | 227,835 | |||
| Income (loss) from operations | 161,295 | |||
| Gain from sale of priority review voucher | 0 | |||
| Interest and other income, net | 28,176 | |||
| Income before income taxes | 189,471 | |||
| Income tax benefit (expense) | -15,360 | |||
| Net income | 204,831 | |||
| Unrealized gain (loss) on available-for-sale securities, net of tax | 642 | |||
| Foreign currency translation | 684 | |||
| Comprehensive income | 206,157 | |||
| Basic (in shares) | 28,944,000 | |||
| Basic (in usd per share) | 7.08 | |||
| Diluted (in shares) | 29,951,000 | |||
| Diluted (in usd per share) | 6.84 | |||
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)